Combined pars plana vitrectomy and Baerveldt glaucoma implant placement for refractory glaucoma

被引:18
作者
Campagnoli, Thalmon R. [1 ]
Kim, Sung Soo [2 ]
Smiddy, William E. [1 ]
Gedde, Steve J. [1 ]
Budenz, Donald L. [3 ]
Parrish, Richard K., II [1 ]
Palmberg, Paul F. [1 ]
Feuer, William [1 ]
Shi, Wei [1 ]
机构
[1] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA
[2] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Ophthalmol, Seoul 135720, South Korea
[3] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA
关键词
glaucoma drainage device; pars plana vitrectomy; refractory glaucoma; neovascular glaucoma; ENDOTHELIAL GROWTH-FACTOR; AHMED VALVE IMPLANTATION; INTRAVITREAL BEVACIZUMAB; CLINICAL-EXPERIENCE; PANRETINAL PHOTOCOAGULATION; MITOMYCIN-C; IRIS NEOVASCULARIZATION; TUBE IMPLANTATION; DRAINAGE DEVICE; TRABECULECTOMY;
D O I
10.3980/j.issn.2222-3959.2015.05.11
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
AIM: To evaluate outcomes of combined pars plana vitrectomy and Baerveldt glaucoma implant (PPV -BGI) placement for refractory glaucoma. METHODS: The medical records of 92 eyes (89 patients) that underwent PPV -BGI were retrospectively reviewed, including 43 eyes with neovascular glaucoma (NVG) and 49 eyes with other types of glaucoma (nonNVG). RESULTS: Outcome measures were visual acuity (VA), intraocular pressure (IOP), glaucoma medical therapy, complications, and success [VA >hand motions (HM), IOP >= 6 mm Hg and <= 21 mm Hg, no subsequent glaucoma surgery]. Cumulative success rates for the non -NVG group and NVG group were 79% and 40% at 1y, respectively (P=0.038). No difference in the rates of surgical success were found between pars plana and anterior chamber tube placement. Preoperative 10P (meantSD). was 30.3 +/- 11.7 mm Hg in the Non-NVG group and 40.0 +/- 10.6 mm Hg in the NVG group, and 10P was reduced to 15 +/- 9.5 mm Hg in the non-NVG group and 15 +/- 10.5 mm Hg in the NVG at 1y. Number of glaucoma medications (mean SD) decreased from 2.7 +/- 1.3 in the non -NVG group and 2.8 +/- 1.3 in the NVG group preoperatively to 0.76 +/- 1.18 in the non -NVG group and 0.51 +/- 1.00 in the NVG group at 1y. Improvement in VA of >= 2 Snellen lines was observed in 25 (27%) eyes, although only 33% of non -NVG eyes and 2.3% of NVG eyes maintained VA better than 20/200 at 1y. Nonclearing vitreous hemorrhage was the most common postoperative complication occurring in 16 (17%) eyes, and postoperative suprachoroidal hemorrhages developed in 5 (5.4%) eyes. CONCLUSION: PPV-BGI is a viable surgical option for eyes with refractory glaucoma, but visual outcomes are frequently poor because of ocular comorbidities, especially in eyes with NVG. The location of tube placement does not influence surgical outcome and should be left to the discretion of the surgeon.
引用
收藏
页码:916 / 921
页数:6
相关论文
共 48 条
[1]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[2]   Management of Neovascular Glaucoma With Panretinal Photocoagulation, Intravitreal Bevacizumab, and Subsequent Trabeculectomy With Mitomycin C [J].
Alkawas, Ayman A. ;
Shahien, Ezzat A. ;
Hussein, Atef M. .
JOURNAL OF GLAUCOMA, 2010, 19 (09) :622-626
[3]   Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment [J].
Avery, Robert L. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :352-354
[4]  
Azuara-Blanco A, 1998, ARCH OPHTHALMOL-CHIC, V116, P808
[5]   Pars plana vitrectomy, endolaser coagulation of the retina and the ciliary body combined with silicone oil endotamponade in the treatment of uncontrolled neovascular glaucoma [J].
Bartz-Schmidt, KU ;
Thumann, G ;
Psichias, A ;
Krieglstein, GK ;
Heimann, K .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1999, 237 (12) :969-975
[6]   Bevacizumab as adjuvant for neovascular glaucoma [J].
Beutel, Julia ;
Peters, Swaantje ;
Lueke, Matthias ;
Aisenbrey, Sabin ;
Szurman, Peter ;
Spitzer, Martin S. ;
Yoeruek, Efdal ;
Grisanti, Salvatore .
ACTA OPHTHALMOLOGICA, 2010, 88 (01) :103-109
[7]   Baerveldt glaucoma implant in the management of refractory childhood glaucomas [J].
Budenz, DL ;
Gedde, SJ ;
Brandt, JD ;
Kira, D ;
Feuer, W ;
Larson, E .
OPHTHALMOLOGY, 2004, 111 (12) :2204-2210
[8]   Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma [J].
Ceballos, EM ;
Parrish, RK ;
Schiffman, JC .
OPHTHALMOLOGY, 2002, 109 (12) :2256-2260
[9]  
Chalam KV, 2002, OPHTHALMIC SURG LAS, V33, P383
[10]   Practice Preferences for Glaucoma Drainage Device Implantation and Cyclodestruction in Australia and New Zealand [J].
Chow, Kent ;
Mora, Justin .
JOURNAL OF GLAUCOMA, 2012, 21 (03) :199-205